Rose McNulty

Early genomic testing could identify the children who are most at risk and provide opportunities to intervene as early as possible.

The case of warm autoimmune hemolytic anemia (AIHA) highlights the potential for life-threatening acute hemolysis if patients do not receive timely treatment.

The rarity of sinonasal cancers presents various challenges for advancing disease management.

With adherence estimated at less than 50% in children, adolescents, and young adults, a recent study stresses the importance of treatment adherence for patients with sickle cell disease receiving hydroxyurea and the benefit for those who do.

Despite the known potential benefits of newborn screening, the exact long-term clinical benefits and cost-effectiveness in large cohorts remain uncertain due to a lack of large-scale longitudinal research.

Current standard modalities for detecting and quantifying monoclonal immunoglobin in patients with cold agglutinin disease lack adequate sensitivity. Heavy chain/light chain assay may be more effective.

After years of dependence on systemic corticosteroids, ruxolitinib treatment was effective for an adolescent patient with graft-versus-host disease (GVHD) who was initially thought to have eosinophilic gastroenteritis.

This retrospective study and prospective follow-up provide insight into predictors of thrombotic episodes in patients with autoimmune hemolytic anemia (AIHA) and indicators that anticoagulant prophylaxis may be beneficial to certain patients.

The Institute for Clinical and Economic Review (ICER) released the report, which supports the long-term value of betibeglogene autotemcel (beti-cel) for the treatment of beta thalassemia.

A recent survey of patients with urticarial vasculitis found that quality-of-life (QOL) impairment is an important factor to consider when putting disease management plans in place.

Clonal cytopenias of undetermined significance often manifest prior to myelodysplastic syndromes (MDS), and a recent study found similarities in the cytokine profiles of the distinct conditions.

Nonspecific clinical symptoms can make identifying eosinophilic gastritis difficult, but detailed examination, biopsy, and testing can rule out other possible causes of eosinophilic infiltration of the gastric mucosa.

As the number of known cancer targets and precision therapies increases, implementing whole-genome sequencing (WGS) into regular clinical practice may benefit patients with metastatic cancer.

While comprehensive genetic profiling has the potential to change the course of certain patients’ cancers, a recent survey found that patients often have difficulty understanding results and their implications.

The combination regimen delivered better overall survival and response rates among patients with myelodysplastic syndromes (MDS).

Additional population-based studies of autoimmune hemolytic anemia and its management are needed to reduce mortality in this patient population.

The prognosis for cholangiocarcinoma remains poor despite advances in targeted therapy, but several targets hold promise for improving treatment strategies and patient outcomes.

A small study of children with eosinophilic esophagitis found that certain patients might benefit from gastric emptying nuclear medicine studies.

Although the autoimmune response that reduces β cell numbers has often been the focus of research in type 1 diabetes (T1D), findings from a new study suggest proinflammatory signaling in islet β cells may play a significant role in disease progression.

Hypomethylating agents are a widely used treatment option in acute myeloid leukemia secondary to myeloproliferative neoplasms (MPNs), but careful monitoring of thromboembolic risk is needed for optimal outcomes.

A recent study identified trends in blood counts, but did not find statistically significant associations between achieving hematological remission and clinical outcomes in polycythemia vera (PV) or essential thrombocythemia (ET).

Real-world patients often differ from those eligible for clinical trials, and comparing results in both populations is a key step in fine-tuning treatment strategies for multiple myeloma.

Multisystem inflammatory syndrome (MIS) in children is a rare condition known to be associated with COVID-19, but more research is needed to identify at-risk patients and guide public health interventions.

Whole-exome and RNA sequencing of early and late multiple myeloma tumor samples aimed to provide insight into disease drivers and phenotypes.

The Diabetes-Specific Risk-Taking Inventory proved useful in assessing risk-taking behavior in adolescents with type 1 diabetes (T1D), but future research on potential interventions is needed.

In patients with BRAF-mutated non–small-cell lung cancer (NSCLC), further research is needed to identify more treatment options that address the scope of subsets in this population.

Research presented at the 2022 American Society of Clinical Oncology Annual Meeting shows White patients with myelodysplastic syndrome (MDS) have worse overall survival outcomes than African American patients, contrary to previous findings in other cancer types.

Creating and validating effective risk assessment models could help facilitate appropriate prophylaxis for hemophilia, but more research is needed to confirm the prognostic value of various clinical risk factors and biomarkers.

A recent review explored current palliative care practices for patients with hematologic cancers compared with solid tumor cancers.

Early results of a multicenter phase 2 trial exploring the efficacy of daratumumab, pomalidomide, dexamethasone, and ixazomib treatment suggest the regimen is safe and effective in relapsed or refractory multiple myeloma (MM).